The drug abuse problem in general and the widespread use of marijuana in particular have focused attention on the chemistry and pharmacology of the plant Cannabis saliva. Although rapid advances have been made in the chemistry and pharmacology of this class of compound called cannabinoids, the mechanisms involved in producing the various central nervous effects have not been established. A few years ago, it was shown that cannabinoids act by binding to a G-protein-coupled receptor in the brain (CB1), and arachidonylethanolamide called anandamide (AN), was identified as the endogenous ligand. The long term goal of this program is to develop the Structure-Activity Relationships (SAR) of ANs which are eicosanoids, and bear no chemical/structural relationship with cannabinoids. We feel the SAR of ANs will be critical for understanding how AN and cannabinoids interact with the same receptor. The present emphasis will be directed toward developing (1) potent agonists and potential antagonists; (2) novel structural analogs; (3) hydroxy-AN analogs as potential metabolites and (4) selective amidase inhibitors. All these goals represent a continuation of the current program which has generated several noteworthy leads.
The specific aims are to (1) continue to examine the SAR of arachidonic acid part of AN; (2) continue to examine the SAR of the ethanolamine part of AN; (3) synthesize hydroxylated AN analogs; (4) develop novel AN/THC analogs; (5) develop a selective and potent amidase inhibitor. The synthesis of these analogs and their subsequent biological evaluation will provide us with SAR in the AN series and will highlight the differences which may exist between this series and THCs and allow a better understanding of their interrelationship. The data could point us in the direction of cannabinoid receptor sub-types and even help in the discovery of an antagonist. In addition they will provide cannabinoid probes for both in vitro and in vivo studies. The proposed study will therefore help in our understanding of the pharmacological action of this important class of compounds.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA008904-06
Application #
6150487
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Hillery, Paul
Project Start
1995-02-01
Project End
2003-01-31
Budget Start
2000-02-01
Budget End
2001-01-31
Support Year
6
Fiscal Year
2000
Total Cost
$128,290
Indirect Cost
Name
Organix, Inc.
Department
Type
DUNS #
City
Woburn
State
MA
Country
United States
Zip Code
01801
Breivogel, Christopher S; Puri, Vanita; Lambert, Jonathan M et al. (2013) The influence of beta-arrestin2 on cannabinoid CB1 receptor coupling to G-proteins and subcellular localization and relative levels of beta-arrestin1 and 2 in mouse brain. J Recept Signal Transduct Res 33:367-79
Bisogno, Tiziana; Burston, James J; Rai, Ravi et al. (2009) Synthesis and pharmacological activity of a potent inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol. ChemMedChem 4:946-50
Breivogel, Christopher S; Lambert, Jonathan M; Gerfin, Steven et al. (2008) Sensitivity to delta9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2 -/- mice. Behav Pharmacol 19:298-307
Bourne, Caryl; Roy, Sucharita; Wiley, Jenny L et al. (2007) Novel, potent THC/anandamide (hybrid) analogs. Bioorg Med Chem 15:7850-64
Wiley, Jenny L; Razdan, Raj K; Martin, Billy R (2006) Evaluation of the role of the arachidonic acid cascade in anandamide's in vivo effects in mice. Life Sci 80:24-35
Ligresti, Alessia; Cascio, Maria Grazia; Pryce, Gareth et al. (2006) New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis. Br J Pharmacol 147:83-91
Bisogno, Tiziana; Cascio, Maria Grazia; Saha, Bijali et al. (2006) Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta 1761:205-12
Kaplan, Barbara L F; Ouyang, Yanli; Herring, Amy et al. (2005) Inhibition of leukocyte function and interleukin-2 gene expression by 2-methylarachidonyl-(2'-fluoroethyl)amide, a stable congener of the endogenous cannabinoid receptor ligand anandamide. Toxicol Appl Pharmacol 205:107-15
Vandevoorde, Severine; Saha, Bijali; Mahadevan, Anu et al. (2005) Influence of the degree of unsaturation of the acyl side chain upon the interaction of analogues of 1-arachidonoylglycerol with monoacylglycerol lipase and fatty acid amide hydrolase. Biochem Biophys Res Commun 337:104-9
Wiley, Jenny L; Smith, Forrest L; Razdan, Raj K et al. (2005) Task specificity of cross-tolerance between Delta9-tetrahydrocannabinol and anandamide analogs in mice. Eur J Pharmacol 510:59-68

Showing the most recent 10 out of 19 publications